Itaconate controls the severity of pulmonary fibrosis.

Administration, Inhalation Adoptive Transfer / methods Adult Aged Animals Bleomycin / administration & dosage Bronchoalveolar Lavage Fluid / immunology Bronchoscopy Carboxy-Lyases / metabolism Case-Control Studies Cells, Cultured Disease Models, Animal Female Fibroblasts Healthy Volunteers Humans Hydro-Lyases / genetics Idiopathic Pulmonary Fibrosis / chemically induced Lung / cytology Macrophages, Alveolar / immunology Male Mice Mice, Knockout Middle Aged Primary Cell Culture Severity of Illness Index Succinates / administration & dosage

Journal

Science immunology
ISSN: 2470-9468
Titre abrégé: Sci Immunol
Pays: United States
ID NLM: 101688624

Informations de publication

Date de publication:
23 Oct 2020
Historique:
received: 10 04 2020
accepted: 29 09 2020
entrez: 24 10 2020
pubmed: 25 10 2020
medline: 21 9 2021
Statut: ppublish

Résumé

Idiopathic pulmonary fibrosis (IPF) is a fatal lung disease in which airway macrophages (AMs) play a key role. Itaconate has emerged as a mediator of macrophage function, but its role during fibrosis is unknown. Here, we reveal that itaconate is an endogenous antifibrotic factor in the lung. Itaconate levels are reduced in bronchoalveolar lavage, and itaconate-synthesizing cis-aconitate decarboxylase expression (

Identifiants

DOI: 10.1126/sciimmunol.abc1884 PMID: 33097591 PMC: PMC7116646
pubmed: 33097591
pii: 5/52/eabc1884
doi: 10.1126/sciimmunol.abc1884
pmc: PMC7116646
mid: EMS110989
pii:
doi:

Substances chimiques

Succinates 0
Bleomycin 11056-06-7
ACOD1 protein, human EC 4.1.1.-
Carboxy-Lyases EC 4.1.1.-
Hydro-Lyases EC 4.2.1.-
Irg1 protein, mouse EC 4.2.1.79
itaconic acid Q4516562YH

Types de publication

Journal Article Observational Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Wellcome Trust
ID : 205949
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 107059
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_PC_19040
Pays : United Kingdom
Organisme : HSRD VA
ID : CDA 13-017
Pays : United States
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Department of Health
ID : CS-2013-13-017
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 205949/Z/17/Z
Pays : United Kingdom

Références

J Exp Med. 2018 Apr 2;215(4):1035-1045
pubmed: 29511063
J Exp Med. 2020 Mar 2;217(3):
pubmed: 31917836
J Exp Med. 2017 Aug 7;214(8):2387-2404
pubmed: 28694385
Nat Rev Dis Primers. 2017 Oct 20;3:17074
pubmed: 29052582
Cell Metab. 2019 Jan 8;29(1):211-220.e5
pubmed: 30293776
Nucleic Acids Res. 2015 Jul 1;43(W1):W566-70
pubmed: 25969447
Nat Rev Immunol. 2016 Sep;16(9):553-65
pubmed: 27396447
Am J Physiol Lung Cell Mol Physiol. 2008 Feb;294(2):L152-60
pubmed: 17993587
J Leukoc Biol. 2006 Mar;79(3):628-38
pubmed: 16415166
Am J Physiol Lung Cell Mol Physiol. 2011 Oct;301(4):L510-8
pubmed: 21743030
Am J Respir Crit Care Med. 2019 Jul 15;200(2):209-219
pubmed: 31051082
Biomed Res Int. 2015;2015:329481
pubmed: 26779535
Oncotarget. 2018 Aug 14;9(63):32098-32107
pubmed: 30181801
Nature. 2018 Apr 5;556(7699):113-117
pubmed: 29590092
J Biol Chem. 2016 Jul 1;291(27):14274-84
pubmed: 27189937
Am J Respir Cell Mol Biol. 2017 May;56(5):667-679
pubmed: 28459387
Eur Respir J. 2011 Dec;38(6):1461-7
pubmed: 21700608
Biotechniques. 2008 Apr;44(4):507-11, 514-7
pubmed: 18476815
Am J Respir Cell Mol Biol. 2016 Jan;54(1):147-9
pubmed: 26274047
J Virol. 2016 Jul 27;90(16):7313-7322
pubmed: 27252532
Nat Rev Immunol. 2014 Feb;14(2):81-93
pubmed: 24445666
Mucosal Immunol. 2017 May;10(3):716-726
pubmed: 27759022
Int J Biochem Cell Biol. 2008;40(3):362-82
pubmed: 17936056
Cell Metab. 2016 Jul 12;24(1):158-66
pubmed: 27374498
Immunity. 2014 Jul 17;41(1):14-20
pubmed: 25035950
Nat Commun. 2017 Feb 23;8:14532
pubmed: 28230051
Front Pharmacol. 2014 May 27;5:123
pubmed: 24904424
J Clin Invest. 2009 Dec;119(12):3713-22
pubmed: 19884654
Eur Respir J. 2015 Sep;46(3):795-806
pubmed: 25976683
Proc Natl Acad Sci U S A. 2013 May 7;110(19):7820-5
pubmed: 23610393
Thorax. 2015 Dec;70(12):1189-96
pubmed: 26286722
Immunity. 2016 Mar 15;44(3):450-462
pubmed: 26982353
J Am Chem Soc. 2011 Oct 19;133(41):16386-9
pubmed: 21919507
J Proteome Res. 2011 May 6;10(5):2238-47
pubmed: 21452902
Immunogenetics. 1995;41(5):263-70
pubmed: 7721348
Cell. 2016 Oct 6;167(2):457-470.e13
pubmed: 27667687
Trends Mol Med. 2016 Apr;22(4):303-316
pubmed: 26979628

Auteurs

Patricia P Ogger (PP)

National Heart and Lung Institute, Imperial College London, London SW7 2AZ, UK.
ORCID: 0000-0002-2698-3565

Gesa J Albers (GJ)

National Heart and Lung Institute, Imperial College London, London SW7 2AZ, UK.
Asthma UK Centre in Allergic Mechanisms of Asthma, London, UK.
ORCID: 0000-0002-8249-6956

Richard J Hewitt (RJ)

National Heart and Lung Institute, Imperial College London, London SW7 2AZ, UK.
Royal Brompton Hospital, Sydney Street, London SW3 6NP, UK.
ORCID: 0000-0003-4294-0052

Brendan J O'Sullivan (BJ)

Queensland Lung Transplant Service, Prince Charles Hospital, Brisbane, Queensland, Australia.
Faculty of Medicine, University of Queensland, Brisbane, Queensland, Australia.
ORCID: 0000-0001-9773-2571

Joseph E Powell (JE)

Garvan-Weizmann Centre for Cellular Genomics, Garvan Institute of Medical Research, Darlinghurst, Sydney, Australia.
Cellular Genomics Futures Institute, University of New South Wales, Kensington, Sydney, Australia.

Emily Calamita (E)

National Heart and Lung Institute, Imperial College London, London SW7 2AZ, UK.
ORCID: 0000-0003-4864-9944

Poonam Ghai (P)

National Heart and Lung Institute, Imperial College London, London SW7 2AZ, UK.

Simone A Walker (SA)

National Heart and Lung Institute, Imperial College London, London SW7 2AZ, UK.

Peter McErlean (P)

National Heart and Lung Institute, Imperial College London, London SW7 2AZ, UK.
ORCID: 0000-0003-4199-3355

Peter Saunders (P)

Royal Brompton Hospital, Sydney Street, London SW3 6NP, UK.
ORCID: 0000-0001-9299-0299

Shaun Kingston (S)

Royal Brompton Hospital, Sydney Street, London SW3 6NP, UK.
ORCID: 0000-0002-7294-2430

Philip L Molyneaux (PL)

National Heart and Lung Institute, Imperial College London, London SW7 2AZ, UK.
Royal Brompton Hospital, Sydney Street, London SW3 6NP, UK.
ORCID: 0000-0003-1301-8800

John M Halket (JM)

Mass Spectrometry Facility King's College London, London SE1 9NH, UK.
ORCID: 0000-0003-2767-303X

Robert Gray (R)

Mass Spectrometry Facility King's College London, London SE1 9NH, UK.
ORCID: 0000-0002-3156-2570

Daniel C Chambers (DC)

Queensland Lung Transplant Service, Prince Charles Hospital, Brisbane, Queensland, Australia.
Faculty of Medicine, University of Queensland, Brisbane, Queensland, Australia.

Toby M Maher (TM)

National Heart and Lung Institute, Imperial College London, London SW7 2AZ, UK.
Royal Brompton Hospital, Sydney Street, London SW3 6NP, UK.
Hastings Centre for Pulmonary Research and Division of Pulmonary, Critical Care and Sleep Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
ORCID: 0000-0001-7192-9149

Clare M Lloyd (CM)

National Heart and Lung Institute, Imperial College London, London SW7 2AZ, UK.
Asthma UK Centre in Allergic Mechanisms of Asthma, London, UK.
ORCID: 0000-0001-8977-6726

Adam J Byrne (AJ)

National Heart and Lung Institute, Imperial College London, London SW7 2AZ, UK. a.byrne@imperial.ac.uk.
Asthma UK Centre in Allergic Mechanisms of Asthma, London, UK.
ORCID: 0000-0003-2736-8174

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Thérapeutique › Traitement médicamenteux › Voies d'administration de substances chimiques et des médicaments › Administration par inhalation › Itaconate controls the severity of pulmonary fibrosis.
questionsmedicales.fr › Techniques d'investigation › Techniques immunologiques › Immunisation passive › Transfert adoptif › Itaconate controls the severity of pulmonary fibrosis.
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Itaconate controls the severity of pulmonary fibrosis.
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Sujet âgé › Itaconate controls the severity of pulmonary fibrosis.
questionsmedicales.fr › Eucaryotes › Animaux › Itaconate controls the severity of pulmonary fibrosis.
questionsmedicales.fr › Acides aminés, peptides et protéines › Peptides › Glycopeptides › Bléomycine › Itaconate controls the severity of pulmonary fibrosis.
questionsmedicales.fr › Techniques d'investigation › Irrigation thérapeutique › Lavage bronchoalvéolaire › Liquide de lavage bronchoalvéolaire › Itaconate controls the severity of pulmonary fibrosis.
questionsmedicales.fr › Procédures de chirurgie opératoire › Procédures de chirurgie thoracique › Procédures de chirurgie pulmonaire › Bronchoscopie › Itaconate controls the severity of pulmonary fibrosis.
questionsmedicales.fr › Enzymes et coenzymes › Enzymes › Lyases › Carbon-carbon lyases › Carboxy-lyases › Itaconate controls the severity of pulmonary fibrosis.
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études cas-témoins › Itaconate controls the severity of pulmonary fibrosis.
questionsmedicales.fr › Cellules › Cellules cultivées › Itaconate controls the severity of pulmonary fibrosis.
questionsmedicales.fr › Techniques d'investigation › Modèles théoriques › Modèles biologiques › Modèles animaux de maladie humaine › Itaconate controls the severity of pulmonary fibrosis.
questionsmedicales.fr › Cellules › Cellules du tissu conjonctif › Fibroblastes › Itaconate controls the severity of pulmonary fibrosis.
questionsmedicales.fr › Personnes › Bénévoles › Volontaires sains › Itaconate controls the severity of pulmonary fibrosis.
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Itaconate controls the severity of pulmonary fibrosis.
questionsmedicales.fr › Enzymes et coenzymes › Enzymes › Lyases › Carbon-oxygen lyases › Hydro-lyases › Itaconate controls the severity of pulmonary fibrosis.
questionsmedicales.fr › Maladies de l'appareil respiratoire › Maladies pulmonaires › Pneumopathies interstitielles › Fibrose pulmonaire idiopathique › Itaconate controls the severity of pulmonary fibrosis.
questionsmedicales.fr › Appareil respiratoire › Poumon › Itaconate controls the severity of pulmonary fibrosis.
questionsmedicales.fr › Systèmes sanguin et immunitaire › Système immunitaire › Phagocytes › Macrophages › Macrophages alvéolaires › Itaconate controls the severity of pulmonary fibrosis.
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › Itaconate controls the severity of pulmonary fibrosis.
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › Souris transgéniques › Souris knockout › Itaconate controls the severity of pulmonary fibrosis.
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Adulte d'âge moyen › Itaconate controls the severity of pulmonary fibrosis.
questionsmedicales.fr › Techniques d'investigation › Techniques in vitro › Techniques de culture › Techniques de culture cellulaire › Culture de cellules primaires › Itaconate controls the severity of pulmonary fibrosis.
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Collecte de données › Enquêtes et questionnaires › Enquêtes de santé › Indicateurs d'état de santé › Acuité des besoins du patient › Indice de gravité de la maladie › Itaconate controls the severity of pulmonary fibrosis.
questionsmedicales.fr › Composés chimiques organiques › Acides carboxyliques › Acides acycliques › Diacides carboxyliques › Succinates › Itaconate controls the severity of pulmonary fibrosis.